Vanguard Group Inc. Acquires 167,708 Shares of Progenics Pharmaceuticals Inc. (PGNX)
Vanguard Group Inc. lifted its holdings in Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) by 4.1% in the second quarter, according to the company in its most recent filing with the SEC. The fund owned 4,300,478 shares of the biotechnology company’s stock after acquiring an additional 167,708 shares during the quarter. Vanguard Group Inc. owned 6.12% of Progenics Pharmaceuticals worth $29,200,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also made changes to their positions in PGNX. UBS Asset Management Americas Inc. lifted its holdings in shares of Progenics Pharmaceuticals by 41.2% in the 1st quarter. UBS Asset Management Americas Inc. now owns 38,724 shares of the biotechnology company’s stock worth $366,000 after acquiring an additional 11,300 shares during the last quarter. Parametric Portfolio Associates LLC lifted its holdings in shares of Progenics Pharmaceuticals by 33.5% in the 1st quarter. Parametric Portfolio Associates LLC now owns 101,249 shares of the biotechnology company’s stock worth $956,000 after acquiring an additional 25,413 shares during the last quarter. JPMorgan Chase & Co. bought a new stake in shares of Progenics Pharmaceuticals in the 1st quarter worth approximately $726,000. Prudential Financial Inc. bought a new stake in shares of Progenics Pharmaceuticals in the 1st quarter worth approximately $1,208,000. Finally, American International Group Inc. lifted its holdings in shares of Progenics Pharmaceuticals by 7.1% in the 1st quarter. American International Group Inc. now owns 42,864 shares of the biotechnology company’s stock worth $405,000 after acquiring an additional 2,835 shares during the last quarter. Hedge funds and other institutional investors own 89.32% of the company’s stock.
A number of equities research analysts have recently weighed in on the stock. Zacks Investment Research lowered shares of Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday. Cantor Fitzgerald reiterated a “buy” rating and set a $15.00 price target on shares of Progenics Pharmaceuticals in a report on Thursday, November 2nd. ValuEngine lowered shares of Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, October 6th. Needham & Company LLC reiterated a “strong-buy” rating and set a $14.00 price target on shares of Progenics Pharmaceuticals in a report on Friday, September 1st. Finally, Aegis reiterated a “buy” rating and set a $14.00 price target on shares of Progenics Pharmaceuticals in a report on Tuesday, August 22nd. Three research analysts have rated the stock with a sell rating, four have given a buy rating and one has issued a strong buy rating to the company. Progenics Pharmaceuticals has an average rating of “Hold” and a consensus price target of $13.20.
TRADEMARK VIOLATION WARNING: This story was published by Watch List News and is owned by of Watch List News. If you are reading this story on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The correct version of this story can be accessed at https://www.watchlistnews.com/vanguard-group-inc-acquires-167708-shares-of-progenics-pharmaceuticals-inc-pgnx/1697417.html.
Shares of Progenics Pharmaceuticals Inc. (NASDAQ PGNX) opened at $5.60 on Friday. Progenics Pharmaceuticals Inc. has a 1-year low of $4.60 and a 1-year high of $11.72. The company has a debt-to-equity ratio of 0.80, a current ratio of 7.86 and a quick ratio of 7.86.
Progenics Pharmaceuticals (NASDAQ:PGNX) last posted its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.22) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.24) by $0.02. Progenics Pharmaceuticals had a negative net margin of 445.81% and a negative return on equity of 67.61%. The company had revenue of $2.70 million during the quarter, compared to analyst estimates of $3.58 million. During the same period in the prior year, the business posted $0.52 EPS. The firm’s revenue was down 95.0% compared to the same quarter last year. equities research analysts expect that Progenics Pharmaceuticals Inc. will post -0.92 earnings per share for the current fiscal year.
Progenics Pharmaceuticals Profile
Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools.
Receive News & Ratings for Progenics Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.